Tag: heart failure

Rehabilitacja kardiologiczna stanowi konieczny etap leczenia większości chorób układu sercowo-naczyniowego. Jej wpływ na wydłużenie życia u pacjentów po zawale serca i z niewydolnością serca udowodniono w wielu badaniach klinicznych [1–3]. Podstawową metodą stosowaną w usprawnianiu pacjentów obciążonych chorobami układu sercowo-naczyniowego jest wy trzymałościowy trening fizyczny, którego intensywność ustala się na podstawie maksymalnego testu wysiłkowego na bieżni ruchomej lub cykloergometrze rowerowym...

Effective treatment of chronic heart failure (CHF) has become a constant challenge for clinicians in the developed countries [1]. One of the therapeutic keystones in CHF, along with angiotensin-converting enzymes inhibitors (ACEI), is use of beta-blockers, which improves both left ventricular (LV) function and survival [2]. In recent years, increased attention has been focused on various circulating biologically active substances, collectively known as plasma biomarkers, and their utility in HF prognosis and therapy monitoring [3]...

Cardiac resynchronization therapy (CRT) has become an accepted method for treating refractory heart failure (HF) in patients with idiopathic or ischemic dilated cardiomyopathy associated with electromechanical asynchrony. In the current American Heart Association (AHA) guidelines, CRT is a class I (level of evidence A) therapy for patients with a left ventricular ejection fraction (LVEF) less than or equal to 35% and a QRS duration greater than or equal to 120 ms, who are New York Heart Association (NYHA) functional Class III or IV despite optimal recommended medical therapy [1, 2]...

Sleep disordered breathing (SDB) is one of the most common and yet largely under-diagnosed co-morbidity in patients with heart failure (HF) [1, 2]. It leads to further deterioration of cardiac function and worsens prognosis [3–6]. SDB may be a potential therapeutic target as its effective treatment improves quality of life, exercise tolerance and, possibly, long term prognosis [5–10]. However, the importance of SDB remains unrecognized and the disorder itself is diagnosed rarely and remains untreated [5]...

Heart failure (HF) is currently one of the most common and rising chronic diseases in developed countries. Total percentage of people with HF reaches 0.4–2% in Europe [1] and among people over the age of 75 it exceeds 10% [2]. In European Union countries the number of patients surpasses 15 million [3] and in Poland 1 million [4]...

The advent of modern treatments in cardiology and the resulting survival benefi t in industrialized countries have considerably increased the size of the population of patients suffering from congestive heart failure (CHF), estimated at over 15 million in the European Union [1]. Coronary artery disease (CAD), hypertension and tachyarrhythmia, usually in the form of atrial fi brillation (AF), are believed to be the most common causative factors of myocardial dysfunction [2–4]...

Hyponatremia defined as serum sodium level < 135 mmol/L, is a common electrolyte abnormality in hospitalized patients, and it is associated with increasing morbidity and mortality. Patients with heart failure (HF) are not exempt from this association, and 19% to 25% of patients with acute decompensated heart failure (ADHF) have hyponatremia [1, 2]...

Między sercem a nerkami istnieje ścisła fizjologiczna oraz patofizjologiczna zależność. Choroby układu sercowo-naczyniowego są głównym czynnikiem chorobowości i śmiertelności pacjentów dotkniętych przewlekłą chorobą nerek (PChN) [1]. Z drugiej strony, dysfunkcja nerek jest uznanym czynnikiem ryzyka chorób układu sercowo-naczyniowego, a progresja niewydolności serca u pacjentów z uszkodzeniem nerek koreluje ze stopniem PChN oraz przewodnieniem [2]...